CN104994860A - 用于治疗医院性肺炎的组合疗法 - Google Patents

用于治疗医院性肺炎的组合疗法 Download PDF

Info

Publication number
CN104994860A
CN104994860A CN201480007538.3A CN201480007538A CN104994860A CN 104994860 A CN104994860 A CN 104994860A CN 201480007538 A CN201480007538 A CN 201480007538A CN 104994860 A CN104994860 A CN 104994860A
Authority
CN
China
Prior art keywords
ceftazidime
avibactam
combination
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480007538.3A
Other languages
English (en)
Chinese (zh)
Inventor
S.达斯
J.李
J.W.穆顿
W.尼克尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashley Connan Tellier First Ltd
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50114393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104994860(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN201910679229.5A priority Critical patent/CN110302203A/zh
Publication of CN104994860A publication Critical patent/CN104994860A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480007538.3A 2013-02-06 2014-02-06 用于治疗医院性肺炎的组合疗法 Pending CN104994860A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910679229.5A CN110302203A (zh) 2013-02-06 2014-02-06 用于治疗医院性肺炎的组合疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761369P 2013-02-06 2013-02-06
US61/761369 2013-02-06
PCT/GB2014/050354 WO2014122468A1 (en) 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910679229.5A Division CN110302203A (zh) 2013-02-06 2014-02-06 用于治疗医院性肺炎的组合疗法

Publications (1)

Publication Number Publication Date
CN104994860A true CN104994860A (zh) 2015-10-21

Family

ID=50114393

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480007538.3A Pending CN104994860A (zh) 2013-02-06 2014-02-06 用于治疗医院性肺炎的组合疗法
CN201910679229.5A Pending CN110302203A (zh) 2013-02-06 2014-02-06 用于治疗医院性肺炎的组合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910679229.5A Pending CN110302203A (zh) 2013-02-06 2014-02-06 用于治疗医院性肺炎的组合疗法

Country Status (13)

Country Link
US (1) US20150374673A1 (enExample)
EP (1) EP2953626A1 (enExample)
JP (1) JP6383367B2 (enExample)
KR (1) KR20150115761A (enExample)
CN (2) CN104994860A (enExample)
AU (1) AU2014213795B2 (enExample)
BR (1) BR112015018360B1 (enExample)
CA (1) CA2897446A1 (enExample)
CL (1) CL2015002180A1 (enExample)
MX (1) MX2015010077A (enExample)
RU (1) RU2684112C2 (enExample)
UA (1) UA115683C2 (enExample)
WO (1) WO2014122468A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物
CN113413367A (zh) * 2021-08-16 2021-09-21 浙江尖峰药业有限公司 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法
CN119818504A (zh) * 2025-01-04 2025-04-15 重庆圣华曦药业股份有限公司 一种头孢哌酮和阿维巴坦的抗菌组合物及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03357B (me) * 2014-11-17 2019-10-20 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijsкih infekcija
JP2018510190A (ja) * 2015-03-31 2018-04-12 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及びそれらの細菌感染症の予防または治療のための使用
EP3281942A4 (en) 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
SG11201909443YA (en) 2017-05-08 2019-11-28 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861110B1 (en) * 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
CN101074235B (zh) * 2006-05-15 2010-05-12 中国药品生物制品检定所 头孢硫脒醇水化合物及其制备方法
CN101245080A (zh) * 2007-02-14 2008-08-20 山东轩竹医药科技有限公司 含有吡唑并三唑的头孢菌素衍生物
US20120058198A1 (en) * 2009-03-26 2012-03-08 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALAIN BONNEFOY等: "In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor", 《JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY》 *
FRANCOISE BRESSOLLE等: "Endotracheal and Aerosol Administrations of Ceftazidime in Patients with Nosocomial Pneumonia: Pharmacokinetics and Absolute Bioavailability", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
LORENTE L.等: "Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review", 《CLINICAL THERAPEUTICS》 *
PREMAVATHY LEVASSEUR等: "In vitro antibacterial activity of the ceftazidime-avibactam(NXL104) combination against pseudomonas aeruginosa clinical isolates", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
SARAH M. DRAWZ等: "Three decades of β-lactamase inhibitors", 《CLINICAL MICROBIOLOGY REVIEWS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物
CN113413367A (zh) * 2021-08-16 2021-09-21 浙江尖峰药业有限公司 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法
CN119818504A (zh) * 2025-01-04 2025-04-15 重庆圣华曦药业股份有限公司 一种头孢哌酮和阿维巴坦的抗菌组合物及其用途

Also Published As

Publication number Publication date
KR20150115761A (ko) 2015-10-14
CL2015002180A1 (es) 2015-11-27
WO2014122468A1 (en) 2014-08-14
EP2953626A1 (en) 2015-12-16
UA115683C2 (uk) 2017-12-11
CN110302203A (zh) 2019-10-08
AU2014213795A1 (en) 2015-07-30
RU2684112C2 (ru) 2019-04-04
BR112015018360A2 (pt) 2017-07-18
RU2015132369A (ru) 2017-03-13
AU2014213795B2 (en) 2016-10-13
JP6383367B2 (ja) 2018-08-29
BR112015018360B1 (pt) 2022-03-22
CA2897446A1 (en) 2014-08-14
US20150374673A1 (en) 2015-12-31
MX2015010077A (es) 2016-01-25
JP2016507547A (ja) 2016-03-10

Similar Documents

Publication Publication Date Title
CN104994860A (zh) 用于治疗医院性肺炎的组合疗法
JP7245289B2 (ja) 細菌感染症の処置方法
TWI690317B (zh) 用於治療抗藥性細菌感染之組合療法
EP3003307B1 (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
Wang et al. In vitro and in vivo activity of d-serine in combination with β-lactam antibiotics against methicillin-resistant Staphylococcus aureus
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
RU2524665C2 (ru) Композиции и способы лечения, включающие цефтаролин
Ueda et al. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration
Li et al. The potential role of fosfomycin in neonatal sepsis caused by multidrug-resistant bacteria
ES2608046T3 (es) Tratamiento de enfermedades asociadas al uso de antibióticos
MacGowan et al. Frontline antibiotic therapy
Fergadaki et al. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae
EP3919059B1 (en) Composition for treating carbapenem antibiotic-resistant acinetobacter baumannii infection
JP2018526455A (ja) 抗生物質療法
HK40012654A (en) Combination therapy for the treatment of nosocomial pneumonia
CA3049723A1 (en) Methods for identifying novel dosing regimens
Kern Antibacterial agents
US11241434B2 (en) Compositions and methods for improving cognition in a subject
US6465428B1 (en) Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
CN115052597A (zh) 抗生素组合疗法
CN107847501A (zh) 抗菌组合物以及方法
Henderson et al. Ceftobiprole
Sharland The potential role of fosfomycin in neonatal sepsis caused by multidrug resistant bacteria Grace Li, Joseph F Standing, Julia Bielicki, William Hope 3, John van den Anker 4, 5, Paul T. Heath, Mike Sharland Paediatric Infectious Diseases Research Group, Institute of Infection and Immunity, St George’s, University of London, Cranmer Terrace, London SW17 0RE 2 UCL Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH 3Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Liverpool L69 3GE
Walsh Optimising use of fosfomycin against multidrug-resistant Pseudomonas aeruginosa
HK1223305B (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
CB03 Change of inventor or designer information

Inventor after: S. Darth

Inventor after: Li Jianguo

Inventor after: Mouton J.W.

Inventor after: W. Nichols

Inventor before: S. Darth

Inventor before: J.Li

Inventor before: Mouton J.W.

Inventor before: W. Nichols

COR Change of bibliographic data
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Sollentuna, Sweden

Applicant after: AstraZeneca AB

Address before: Sollentuna, Sweden

Applicant before: Ashley Connan Tellier first Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170721

Address after: Sollentuna, Sweden

Applicant after: Ashley Connan Tellier first Ltd.

Address before: Swedish Sodertalje

Applicant before: ASTRAZENECA AB

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151021